TheStreet.com also likes this biotech, recently noting, “A clear take out of the February highs, just above $117.65, could provide the spark needed to send the biotech stock sharply higher.”
Celgene (CELG)
From Nate’s Notes
Despite providing some very encouraging guidance at the JP Morgan Conference earlier this month, I am afraid that Celgene’s stock has been slowly melting along with the rest of the sector in response to Trump’s comments regarding the pharmaceutical industry.
That being said, the company is continuing to fire on all cylinders. Since we are currently a little underweighted in this “best of breed” stock, I am taking advantage of the situation to add a few more shares to both Portfolios this month (but will not be afraid to turn around and sell them in a hurry if Trump ends up putting forth a plan that is clearly going to send the biotech sector into a more pronounced tailspin).
Nate Pile, Nate’s Notes, www.NotWallStreet.com 707-433-7903, January 20, 2017